Neuromyelitis Optica - 17 Studies Found
| Enrolling by invitation |
: Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders :
|
| NOT_YET_RECRUITING |
: Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA� During Pregnancy : : 2024-11-21 : Enrolled female participants with NMOSD who were exposed to UPLIZNA during pregnancy will be assessed.No study drug will be administered. |
| NOT_YET_RECRUITING |
: Inebilizumab in Acute Neuromyelitis Optica Spectrum Disorders : : 2024-11-21 : Inebilizumab: 300mg IV on Day1 and Day 15.The first dose of inelizumab is given during IVMP. |
| RECRUITING |
: Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD : Neuromyelitis Optica : 2024-11-21 : NMOSDCopilot includes active tests for walking, cognition, dexterity and vision, and e-questionnaires related to pain, fatigue, quality of life, bladd |
| RECRUITING |
: Pediatric NMOSD Observational Study : Neuromyelitis Optica : 2024-11-21 |
| RECRUITING |
: In Vitro Study of the Biological and Immunological Activity of Imotopes� Candidates on Blood Cells of Patients With Stabilized NMO : Neuromyelitis Optica : 2024-11-21 : The patients will be asked to provide at least 2 peripheral blood samples of approximately 100 milliliters each time, with a minimum of 14 days interv |
| COMPLETED |
: Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD) : Neuromyelitis Optica Spectrum Disorder : 2024-11-21 : IV, once every 12 weeks (Q12W) |